Merck & Co. stock heads into the open after a 0.8% gain

At the close on September 16, 2026, Merck & Co. stock finished near USD 143.79 on the NYSE, up around 0.8% on the day. The shares outpaced the Dow Jones Industrial Average, which fell about 1.2% in the same session, ahead of upcoming quarterly results in late October.

Merck & Co. stock closed at approximately USD 143.79 on the New York Stock Exchange on September 16, 2026, up about 0.8% from the prior session. The shares moved within an intraday range near USD 143.50 to USD 144.97, with the close sitting closer to the upper end of the day’s band per NYSE data. Compared with the Dow Jones Industrial Average, which fell about 1.21% on September 16, 2026, Merck & Co. stock showed relative strength heading into today’s session.

September 16, 2026 in numbers

Merck & Co., Inc. (ISIN US58933Y1055, NYSE: MRK) shares recently registered a closing level around USD 143.79 on September 16, 2026, leaving them modestly below several fair value estimates around USD 150 per share cited by research platforms. As Simply Wall St reported on September 16, 2026, one widely followed narrative pegs Merck’s fair value at about USD 150.42 per share, implying that the recent close near USD 143.79 reflects roughly 4 percent perceived undervaluation. The same report highlights a 30-day share price return of about 5.85% and a 90-day return near 24.56%, indicating that the stock has clearly outperformed many defensive healthcare peers over the past quarter. In the broader market, the Dow Jones Industrial Average dropped around 630 points, or 1.21%, to roughly 51,462 on September 16, 2026, according to Capital Futures, underscoring Merck’s defensive profile in a weaker session for the index.

Upcoming catalysts today and beyond

Looking ahead, Merck’s next scheduled quarterly results are due on October 29, 2026, with analysts expecting earnings of about USD 2.27 per share for the September quarter, compared with USD 2.58 per share a year earlier, as outlined by Barchart. The same overview notes that Wall Street currently models full-year 2026 earnings of about USD 2.76 per share, significantly below the prior-year level, which keeps regulatory and patent developments in focus for the stock. Into today’s session, investors monitor broader healthcare sector sentiment and movements in the Dow Jones Industrial Average after its decline on September 16, 2026, given Merck’s role as a large defensive constituent.